1 in 9 Us Adults Now Takes Weight-Loss Drugs. Experts Say America's Obesity Crisis Is Far From Over

An estimated one in nine US adults is currently taking a glucagon-like peptide-1 (GLP-1) receptor agonist, as drugs such as semaglutide and tirzepatide reshape obesity treatment. Their growing use may be contributing to a decline in US obesity prevalence for the first time in decades, although severe obesity continues to rise. But a new report warns that medication alone will not reverse a crisis affecting more than one billion people worldwide.
The report, published in JAMA following a summit in Chicago in May 2026, brings together perspectives from more than 50 multidisciplinary experts on the biological, social and environmental factors driving obesity. Its authors say the apparent decline in US obesity prevalence sits alongside a worrying rise in severe obesity, underlining why treatment and prevention need to extend beyond prescriptions.
Why Weight-Loss Drugs Are Not the Whole Answer
GLP-1 receptor agonists mimic a gut hormone involved in appetite and blood sugar regulation. They can reduce hunger and food cravings, increase feelings of fullness and help some patients lose a substantial amount of weight. Clinical trials have also found benefits for cardiovascular and metabolic health in certain groups.
However, the report identifies barriers that limit their reach. High prices and restrictive insurance coverage can make treatment inaccessible, while nausea, vomiting, diarrhoea and gallbladder problems can make it difficult for some people to continue. Obesity is a chronic condition, and patients may need sustained treatment to maintain weight loss, making long-term access and adherence important considerations.
The authors also raise concerns about online sales of unapproved compounded versions and other inadequately studied peptides. People considering these medicines should seek advice from a qualified healthcare professional rather than relying on unverified products or dosing instructions.
Obesity Is Shaped by More Than Individual Choices
The report argues that obesity should be understood as a chronic disease influenced by biological, behavioural and environmental factors, rather than simply a failure of willpower.
Food environments are one part of the problem. Ultra-processed foods account for approximately 55% of the US diet, according to the report. These products are often inexpensive, widely available and energy-dense, although the precise contribution of ultra-processed foods to obesity remains an area of scientific debate.
Changes in daily life also matter. More sedentary work, motorised transport, screen-based leisure, disrupted sleep and limited access to affordable nutritious food can make weight management harder. Genetic factors and the body's biological responses to weight loss can also influence a person's susceptibility to obesity and the likelihood of regaining weight.
The scale of the problem extends beyond adults. Around one in five US children has obesity, while approximately two-thirds of people living with obesity worldwide are in low- and middle-income countries. The report therefore calls for prevention strategies that account for differences in income, healthcare access and local food environments.
What Experts Say Needs to Change
The authors recommend a coordinated response involving healthcare systems, governments, schools, communities and the food industry. Potential measures include clearer front-of-package nutrition warnings, restrictions on marketing unhealthy foods to children, improved school nutrition standards and stronger food assistance programmes.
They also call for better access to evidence-based obesity care, training for clinicians to reduce weight stigma and research that measures more than changes on the scales. Fewer than 1% of people eligible for metabolic or bariatric surgery undergo the procedure, despite evidence of its long-term benefits, including increased life expectancy.
The central message is that newer medicines offer an important treatment option, but they cannot by themselves change the conditions that contribute to obesity. Sustained progress will require effective medical care alongside policies that make healthier choices more accessible.